Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

Blanc, J. F.Meyer, T.Cheng, A-L.El-Khoueiry, A. B.Cicin, I.Chen, Y.Bolondi, L.2024-06-122024-06-1220180923-75341569-8041https://hdl.handle.net/20.500.14551/2677943rd ESMO Congress (ESMO) -- OCT 19-23, 2018 -- Munich, GERMANY[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)Conference Object29237237Q1WOS:000459277301282